Table 5.
Relation of serum DKK1 and AREG concentrations to some tumor characteristics in HCC group
| Serum DKK1 concentration | Serum AREG concentration | |||||
|---|---|---|---|---|---|---|
| Mean ± SD | P | Median | Range | P | ||
| Performance status | 1 | 9.81 ±2.2 | <0.001 | 14.44 | 5.96 - 36.68 | 0.305 |
| 2 | 12.13 ±1.9 | 13.73 | 6.98 – 43.44 | |||
| 3 | 14.59±0.8 | 8.33 | 5.46 – 38.88 | |||
| Ascites | Absent | 11.3 ± 2.2 | 0.775 | 14.44 | 5.96 – 43.44 | 0.557 |
| Mild | 10.7 ±2.9 | 13.73 | 6.98 – 26.39 | |||
| Moderate | 11.4 ±2.8 | 8.33 | 5.46 - 26.81 | |||
| Marked | 12.4 ±4.0 | 26.07 | 13.26 - 38.88 | |||
| Metastasis | Absent | 11.7± 2.2 | 0.442 | 17.18 | 6.64 - 43.44 | 0.024 |
| Present | 11.0± 2.6 | 10.26 | 5.46 - 31.88 | |||
| Portal vein thrombosis | Absent | 11.2 ± 2.4 | 0.788 | 15.42 | 5.46 – 43.44 | 0.012 |
| Present | 11.0 ± 2.9 | 12.59 | 7.65 – 25.96 | |||
| BCLC | A | 10.9 ±1.6 | 0.966 | 14.53 | 10.18 – 18.45 | 0.489 |
| B | 11.0 ± 2.7 | 14.02 | 5.96 – 36.68 | |||
| C | 11.2 ± 2.5 | 14.68 | 6.98 – 43.44 | |||
| D | 11.5 ±3.1 | 8.33 | 5.46 – 38.88 | |||
DKK1: Dickkopf-1, AREG: amphiregulin, HCC: hepatocellular carcinoma, BCLC: Barcelona clinic liver cancer staging